GlassScriptPhysician profile
David T Wakabayashi
NPI 1013072396
$4,977.76
in general payments reported to CMS, 2019-2025
13 companies · $925 in 2025
The $925 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $265 · 2021: $879 · 2022: $936 · 2023: $745 · 2024: $956 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $999.51 | 2021-2025 | Total30, Dailies Total1, Precision 1 |
| Menicon America INC | $679.90 | 2019-2022 | |
| Coopervision INC. | $651.43 | 2020-2025 | Myday Contact Lens, Misight Contact Lens, Onefit Contact Lens |
| Bausch & Lomb Americas INC. | $593.16 | 2022-2025 | Infuse, Alden Scleral Zenlens |
| Sight Sciences, INC. | $452.93 | 2021-2023 | Tearcare System |
| Johnson & Johnson Vision Care, INC. | $422.37 | 2022-2025 | Acuvue |
| Glaukos Corporation | $262.97 | 2022-2025 | Idosetr, Photrexa |
| Lkc Technologies, INC. | $242.38 | 2023-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $170.24 | 2021 | |
| Maculogix, INC. | $150.88 | 2019 | |
| Biotissue Holdings INC. | $150.27 | 2024 | |
| Nova Eye, INC. | $125.00 | 2025 | |
| Optos, INC. | $76.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wakabayashi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.